302610
Intentional Abuse of Select Opioids Reported to a Single Poison Center
Methods: The PC database was queried for patients >=13 years between calendar years (CY) 2009-2013 for the following opioids: buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, tapentadol, and tramadol. Demographic, geographical, exposure, and clinical characteristics were assessed.
Results: A total of 2,868 intentional exposures were identified, of which hydrocodone (35.2%), oxycodone (23.5%), and tramadol (18.8%) were most frequently abused. While the distribution by gender was similar in 13-19 year and 20-39 year age groups, women accounted for 60.8% and 67.5% of intentional exposures in those 40-59 and >=60 years of age, respectively. Between 2009 and 2013, the greatest change was identified in those 40-59 and >=60 years of age with increases of 57.4% and 77.4%, respectively. Most patients were either in/en-route to a healthcare facility (83.4%) or referred to one by the PC (13.3%) due to the exposure.
Discussion: While the overall call volume showed a slight increase with 16.4 additional exposures per year, the rates were greatest in women ages 40-59 (11.9 increased exposures/month). Continued surveillance of epidemiological trends of intentional opioid medications abuse through PC data may provide insight into at risk populations for intentional overdose.
Learning Areas:
Clinical medicine applied in public healthEpidemiology
Public health or related research
Learning Objectives:
Describe recent trends in opioid abuse.
Identify subgroups with greater risk of opioid abuse.
Keyword(s): Prescription Drug Abuse and Misuse, Epidemiology
Qualified on the content I am responsible for because: I am the epidemiologist at the poison center and my main interests involve designing and analyzing studies that bridge toxicology and epidemiology. I have extensive experience with managing databases and using the data our poison center provides to address emerging public health concerns.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.